You are here
Home » News Category » In the News
January 14, 2019
Experiments involving just a few patients have hinted at it, and research on one type of tumor at a time has supported it, but a large study has now delivered the strongest evidence yet about how to identify cancer patients who are likely to benefit from a particular form of immunotherapy: count.
January 10, 2019
Patients with cancer and comorbidities are routinely left out of clinical trial discussions, offers and participation, according to results of a study published in JAMA Oncology.
At least 60% of trial eligibility exclusions are related to patient comorbidities or performance status, according to study background.
Those statistics could start to change because of the implementation of new eligibility guidelines for clinical trials, due in part to this and other studies.
January 10, 2019
How do you make cancer clinical trials available to more patients?
A new study published today in JAMA Oncology and led by Dr. Joseph Unger at Fred Hutchinson Cancer Research Center offers a tantalizing solution: loosen up the strict eligibility criteria.
January 8, 2019
Executive Summary
Agency staff discuss how they offer early development advice to sponsors before a breakthrough decision is made and reassure them if the status is denied.
Sponsors may desire breakthrough status because of the perks that come with it, but US FDA officials said promising non-breakthrough products also could receive a lot of attention to speed them to market.
Billy Dunn, director of the Office of Neurology Products, said his staff does not approach an application differently whether or not it obtains breakthrough status.
January 3, 2019
Executive Summary
Siding with coalition of hospitals, judge ruled that HHS lacked authority to cut Medicare reimbursement for drugs purchased at 340B prices. That should change the dynamics of the 340B reform debate heading into 2019 – but don’t expect the Trump Administration to back down on its push to rein in what it sees as abuses of the discount.
January 2, 2019
Executive Summary
Synthetic control group derived from historical clinical trial data could augment smaller randomized trials and yield better information than single-arm studies, but this approach should not be viewed as a substitute for randomized trials where feasible, US FDA officials said at a Friends of Cancer Research meeting.
December 17, 2018
The US Food and Drug Administration (FDA) announced Monday that Dr. Amy Abernethy will replace Rachel Sherman as Principal Deputy commissioner of Food and Drugs – the highest position at the agency that is not a political appointee.
December 17, 2018
One of the leading voices in using health data to advance targeted treatments known as precision medicine has been tapped for the second-highest post at the FDA.
Amy Abernethy, chief medical officer for Flatiron Health, will join the Food and Drug Administration as its principal deputy commissioner early next year, FDA Commissioner Scott Gottlieb announced Dec. 17. She will replace Rachel Sherman, a longtime FDA staffer who is retiring in January.
December 17, 2018
Executive Summary
O’Brien assumes role from his late colleague and friend Dan Best as HHS closes out administrative items in the blueprint.
The Trump Administration appears to be ramping up towards some kind of action on drug pricing early in the New Year.
Over the last two weeks, HHS Secretary Alex Azar has been posting regular pictures of meetings with a variety of stakeholders on the issue of drug prices.
December 17, 2018
Executive Summary
Abernethy comes to FDA from Flatiron Health, which develops oncology-specific electronic health record software and real-world evidence for cancer research. She succeeds FDA veteran Rachel Sherman, who will retire from the agency in January.
Pages
